Dendritic cell immunotherapy of prostate cancer: Preclinical models and early clinical experience

Cancer Research, Therapy and Control

Volumn 11, Issue 1, 2001, Pages 1-10

  Laus, Reiner ^a   Yang, Demao M ^b   Ruegg, Curtis L ^b   Shapero, Michael H ^b   Slagle, Paul H ^b   Small, Eric ^b   Burch, Patrick ^b   Valone, Frank H ^b  

^a Dendreon   (United States)

^b NONE

Author keywords

Autoimmunity; Dendritic cell; PAP; Prostate; Tumor immunotherapy

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DENDRITIC CELL; DISEASE MARKER; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; MALE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATITIS; RAT; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 0035073360     PISSN: 10640525     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Grabbe S, Beissert S, Schwarz T, Granstein R. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy. Immunol Today 1995;16:117-20.
2. Stingl G, Bergstresser PR, Dendritic cells: a major story unfolds. Immunol Today 1995;16(7):330-3.
3. Shurin MR. Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 1996;43(3): 158-64.
4. Kuciel R, Mazurkiewicz A, Ostrowski WS, Stachura J, Steuden I, Szkudlarek J, et al. Characterization of anti-prostatic acid phosphatase monoclonal antibody and its medical significance. Biotechnol Appl Biochem 1988;10(3):257-72.
5. Lam KW, Li CY, Yam LT, Sun T, Lee G, Ziesmer S. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate 1989;15(1):13-21.
6. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90(8):3539-43.
7. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma [see comments]. Nature 1993;362(6422):755-8.
8. Isaacs JT, Isaacs WB, Feitz WF, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986;9(3):261-81.
9. Thomas WD, Hersey P. CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95). Int J Cancer 1998;75(3):384-90.
10. Kajino K, Kajino Y, Greene MI. Fas- and perforin-independent mechanism of cytotoxic T lymphocyte. Immunol Res 1998;17(1-2):89-93.
11. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997;15:297-322.
12. Morisaki T, Morton D, Uchiyama A, Yuzuki D, Barth A, Hoon D. Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma. Cancer Immunol Immunother 1994;39:172-8.
13. Brossart P, Bevan MJ. Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide. J Exp Med 1996;183(6):2449-58.
14. Topalian SL. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr Opin Immunol 1994;6(5):741-5.
15. Armstrong TD, Clements VK, Ostrand-Rosenberg S. MHC class II-transfected tumor cells directly present antigen to tumor- specific CD4+ T lymphocytes. J Immunol 1998;160(2):661-6.
16. Casas-Ingaramo A, Depiante-Depaoli M, Pacheco-Rupil B. Activation of cytotoxic cells by syngeneic prostate antigens in experimental autoimmune vesiculo-prostatitis. Autoimmunity 1991;9:151-7.
17. Liu KJ, Chatta GS, Twardzik DR, Vedvick TS, True LD, Spies AG, et al. Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy. J Immunol 1997;159(1):472-80.
18. Chatta G, Liu K, Spies G, Vihko P, Cheever M. Induction of immunity to rat prostatic acid phosphatase (PAP): Implications for prostate cancer immunotherapy. Proc AACR 1997:2703a.
19. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997;159(7):3113-7.
20. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells. Nat Med 1996;2(1 ): 52-8.
21. Markowicz S, Engleman EG. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 1990;85(3):955-61.
22. Peshwa M, Page L, Qian L, Yang D, van Schooten W. Generation and ex vivo expansion of HTLV-1 specific CD8+ cytotoxic T-lymphocytes for adoptive immunotherapy. Biotechnol Bioeng 1996:50:529-40.
23. Valone F, Small E, Peshwa M, Strang G, Laus R, Ruegg C, et al. Immunotherapy of hormone refractory prostate cancer (HRPC) with prostatic acid phosphatase (PAP)-loaded dendritic cells (APC8015). Proc ASCO 1999;18:312a.
24. Burch P, Kaur J, Valone F, Peshwa M, Gastineau M. Soluble antigen boost after dendritic cell infusion for immunotherapy of hormone refractory prostate cancer: a phase I trial. Proc AACR 1999;40:86a.